Dasatinib + Quercetin (Senolytic)

Research indicates that the combination of dasatinib and quercetin (D+Q) represents one of the most studied senolytic therapies for targeting cellular senescence. Studies suggest this drug combination works by exploiting the metabolic vulnerabilities of senescent cells, which rely on enhanced pro-survival pathways to resist natural cell death. Dasatinib, originally developed as a cancer therapy, inhibits multiple tyrosine kinases, while quercetin, a natural flavonoid, targets BCL-2 family proteins that prevent apoptosis.

Small human trials have investigated D+Q in various conditions including idiopathic pulmonary fibrosis, diabetic kidney disease, and age-related frailty. Research suggests the combination may reduce senescent cell burden and inflammatory markers while improving some functional outcomes. However, studies remain limited in scope and duration, with most trials involving fewer than 30 participants and following patients for only a few months.

The therapy requires careful medical supervision due to dasatinib's potential for serious side effects including bleeding, fluid retention, and pulmonary complications. Research protocols typically use intermittent dosing (such as 3 consecutive days every few weeks) rather than continuous treatment, though optimal dosing regimens remain under investigation. While promising, larger and longer-term studies are needed to establish both the safety and efficacy profile of this senolytic combination.